Sysmex

Skip Navigation

SearchMenu

About Sysmex

Press Releases

Research & Development Research & Development
Feb. 15, 2016

Sysmex and Eisai enter comprehensive agreement to create next-generation diagnostic reagents in the field of dementia

  Sysmex Corporation (Headquarters: Kobe, Chairman and CEO: Hisashi Ietsugu, “Sysmex”) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) jointly announced that the two companies have entered into a comprehensive non-exclusive collaboration agreement aimed at the creation of new diagnostics in the field of dementia.

  While diagnosis of Alzheimer’s disease is sometimes made by using tests such as brain imaging examinations and cerebrospinal fluid examinations, various issues such as the insufficient number of facilities for examinations, the high cost, and the invasiveness of the testing remain to be addressed. As such, there is a need for the development of technologies that will enable diagnoses to be made in a manner that is easy, affordable and less invasive.

  Sysmex possesses diverse expertise and know-how in the field of clinical diagnostics as well as effective technologies for highly sensitive detection of genetic, protein and cellular biomarkers in blood samples. Meanwhile, Eisai has a wealth of experience and knowledge cultivated though more than 30 years of drug discovery activities in the field of dementia as well as providing product-related information for the Alzheimer's disease / dementia with Lewy bodies treatment* Aricept®.

  Leveraging each other's technologies and knowledge, the two companies aim to discover next-generation diagnostics that will enable early diagnosis, selection of treatment options and the regular monitoring of the effects of treatment for dementia. In collaboration with Eisai, Sysmex will lead the development of diagnostics, and will exclusively market these diagnostics worldwide after receiving regulatory approval. Eisai will receive payments for meeting development milestones, launching products, as well as royalties on sales, and Eisai will utilize these next-generation diagnostics for drug discovery and development in the field of dementia.

  Through this collaboration, Sysmex and Eisai aim to create new value in prevention, diagnosis and treatment of dementia, and to further contribute to addressing the diverse needs of, and increasing the benefits provided to, patients and their families.


* Indication of Aricept for the treatment of dementia with Lewy bodies is approved only in Japan. 


<Notes to editors>
1. About Sysmex
  Sysmex provides customers in over 190 countries around the world with products and solutions for the testing of blood, urine and cell samples. As an integrated company which develops and manufactures the instruments, reagents and software that are needed for in vitro diagnostics, along with the necessary sales and support networks, Sysmex promotes research and technological development to create high value testing and diagnostic technologies in various clinical fields including oncology and chronic disease.
  For more information about Sysmex, please visit: http://www.sysmex.co.jp/en

2. About Eisai
  Eisai Co., Ltd. is a research-based pharmaceutical company that discovers, develops and markets products worldwide. Guided by its corporate mission of “giving first thought to patients and their families, and to increasing the benefits that health care provides,” all Eisai employees aspire to meet the various needs of global health care as representatives of a “human health care (hhc) company” that is capable of making a meaningful contribution under any healthcare system. 
  For more information about Eisai, please visit: http://www.eisai.com
 

*Information contained in the press release is current as of the date of the announcement,
but may be subject to change without prior notice.

Back to "Press Releases"